LONDON: Global pharmaceutical giant Novartis is harnessing the power of data to develop new drugs.
“We are experiencing a data science revolution that we need to harness,” says Dr. Luca Finelli, who is leading the Predictive Analytics and Global Drug Development.
His team has developed a new platform called Nerve Live, which uses the latest advances in computing technology and is designed to help Novartis leverage its huge data pool.
“In reality, we are a data company,” Dr. Finelli explains.
He added “We are used to generating and working with huge amounts of data, analyzing it, and using this knowledge to research and develop new therapies. If we are able to bring our data into one place and tap into the latest computing technologies, we can generate new insights that in the past were difficult to obtain because our data was locked in silos.”
